| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.02. | GSK backs siRNA modality through $1bn Frontier deal | ||
| 24.02. | FDA accepts Beren Therapeutics' NDA for Niemann-Pick disease | ||
| 24.02. | AbbVie announces $380m investment in North Chicago API facilities | ||
| 23.02. | Gilead acquires CAR-T specialist Arcellx for $7.8bn | ||
| 23.02. | EU pledges €225m to develop next generation of flu vaccines | ||
| 23.02. | Novo Nordisk flags board members for re-election amid restructuring efforts | ||
| 23.02. | AstraZeneca's Calquence plus venetoclax gains approval in US to treat CLL | ||
| 23.02. | Roche receives FDA acceptance for giredestrant combo NDA | ||
| 20.02. | Ex-Trump official-ran Altesa secures $75m in Series B funding round | ||
| 20.02. | WHO wants improved universal vaccines to win global influenza battle | ||
| 20.02. | Boehringer Ingelheim and NIPER sign MoU on pharmaceutical research | ||
| 20.02. | Syngene and VivaMed collaborate on therapeutic programmes | ||
| 19.02. | Valneva's Lyme disease vaccine offers beacon of hope amid 2025 sales dip | ||
| 19.02. | J&J to build $1bn US CGT manufacturing site in Pennsylvania | ||
| 19.02. | Novartis enters licensing agreement with UNP for peptide therapeutics | ||
| 19.02. | MSD and Mayo Clinic team up to advance AI in drug development | ||
| 18.02. | FDA to review Moderna's flu jab on agency pivot | ||
| 18.02. | Novo expands injectable Wegovy offering with European higher dose approval | ||
| 18.02. | Evogene and QUT partner on AI-based cancer therapies | ||
| 18.02. | The China factor: US pharma group campaigns for increased competitiveness | ||
| 18.02. | J&J's Rybrevant Faspro gains FDA approval for new dosing in NSCLC | ||
| 17.02. | Pricing and reimbursement delays continue to impact biopharma revenue streams | ||
| 17.02. | Pharma companies venture further afield in search of R&D | ||
| 17.02. | Teijin and Aska Pharmaceutical to co-develop gynaecological drugs | ||
| 17.02. | ExCellThera secures German NUB Status 1 listing for Zemcelpro |